Cargando…

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report

BACKGROUND: Chemoresistance generally develops in patients with advanced epithelial ovarian cancer, and the prognosis is still very poor, with an expected survival time of less than one year. For this population of individuals, there is currently no standard protocol for clinical benefit. CASE PRESE...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Yuan, Guan, Ping, Li, Dan, Tan, Longjing, Pang, Haowen, Wen, Qinglian, Chen, Ping, Zhang, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797826/
https://www.ncbi.nlm.nih.gov/pubmed/36591480
http://dx.doi.org/10.3389/fonc.2022.1071383
_version_ 1784860768191119360
author Bian, Yuan
Guan, Ping
Li, Dan
Tan, Longjing
Pang, Haowen
Wen, Qinglian
Chen, Ping
Zhang, Zhenhua
author_facet Bian, Yuan
Guan, Ping
Li, Dan
Tan, Longjing
Pang, Haowen
Wen, Qinglian
Chen, Ping
Zhang, Zhenhua
author_sort Bian, Yuan
collection PubMed
description BACKGROUND: Chemoresistance generally develops in patients with advanced epithelial ovarian cancer, and the prognosis is still very poor, with an expected survival time of less than one year. For this population of individuals, there is currently no standard protocol for clinical benefit. CASE PRESENTATION: We report a case of an elderly woman diagnosed with stage IIIC high-grade serous ovarian cancer (HGSOC). During a follow-up time of 6 years, the patient initially received multiple sequential courses of chemotherapy with platinum-based regimens and with no maintenance therapy. Similar to most patients with advanced HGSOC, she developed platinum resistance and experienced poor treatment results with a short progression-free survival (PFS). Ultimately, we gave the patient traditional non-platinum-based chemotherapy with bevacizumab and high-dose-rate interstitial brachytherapy followed by olaparib as a maintenance therapy. Up to now, the patient did response well to the treatment, and the PFS had exceeded 12 months. CONCLUSION: High-dose-rate interstitial brachytherapy combination with PARP inhibitors may be an option for isolated chemoresistant recurrent epithelial ovarian cancer.
format Online
Article
Text
id pubmed-9797826
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97978262022-12-30 Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report Bian, Yuan Guan, Ping Li, Dan Tan, Longjing Pang, Haowen Wen, Qinglian Chen, Ping Zhang, Zhenhua Front Oncol Oncology BACKGROUND: Chemoresistance generally develops in patients with advanced epithelial ovarian cancer, and the prognosis is still very poor, with an expected survival time of less than one year. For this population of individuals, there is currently no standard protocol for clinical benefit. CASE PRESENTATION: We report a case of an elderly woman diagnosed with stage IIIC high-grade serous ovarian cancer (HGSOC). During a follow-up time of 6 years, the patient initially received multiple sequential courses of chemotherapy with platinum-based regimens and with no maintenance therapy. Similar to most patients with advanced HGSOC, she developed platinum resistance and experienced poor treatment results with a short progression-free survival (PFS). Ultimately, we gave the patient traditional non-platinum-based chemotherapy with bevacizumab and high-dose-rate interstitial brachytherapy followed by olaparib as a maintenance therapy. Up to now, the patient did response well to the treatment, and the PFS had exceeded 12 months. CONCLUSION: High-dose-rate interstitial brachytherapy combination with PARP inhibitors may be an option for isolated chemoresistant recurrent epithelial ovarian cancer. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9797826/ /pubmed/36591480 http://dx.doi.org/10.3389/fonc.2022.1071383 Text en Copyright © 2022 Bian, Guan, Li, Tan, Pang, Wen, Chen and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bian, Yuan
Guan, Ping
Li, Dan
Tan, Longjing
Pang, Haowen
Wen, Qinglian
Chen, Ping
Zhang, Zhenhua
Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
title Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
title_full Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
title_fullStr Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
title_full_unstemmed Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
title_short Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
title_sort interstitial brachytherapy combined with parp inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797826/
https://www.ncbi.nlm.nih.gov/pubmed/36591480
http://dx.doi.org/10.3389/fonc.2022.1071383
work_keys_str_mv AT bianyuan interstitialbrachytherapycombinedwithparpinhibitorsinthetreatmentofchemoresistantrecurrentepithelialovariancanceracasereport
AT guanping interstitialbrachytherapycombinedwithparpinhibitorsinthetreatmentofchemoresistantrecurrentepithelialovariancanceracasereport
AT lidan interstitialbrachytherapycombinedwithparpinhibitorsinthetreatmentofchemoresistantrecurrentepithelialovariancanceracasereport
AT tanlongjing interstitialbrachytherapycombinedwithparpinhibitorsinthetreatmentofchemoresistantrecurrentepithelialovariancanceracasereport
AT panghaowen interstitialbrachytherapycombinedwithparpinhibitorsinthetreatmentofchemoresistantrecurrentepithelialovariancanceracasereport
AT wenqinglian interstitialbrachytherapycombinedwithparpinhibitorsinthetreatmentofchemoresistantrecurrentepithelialovariancanceracasereport
AT chenping interstitialbrachytherapycombinedwithparpinhibitorsinthetreatmentofchemoresistantrecurrentepithelialovariancanceracasereport
AT zhangzhenhua interstitialbrachytherapycombinedwithparpinhibitorsinthetreatmentofchemoresistantrecurrentepithelialovariancanceracasereport